A smaller share base meets a new round of awards
Redcentric (LSE:RCN), the UK IT managed services provider, continued buying back its own shares last week, with a 16 November notice confirming a purchase made on 13 November and leaving 101,283,455 voting shares in issue. Those daily notices are routine, but they sit alongside a less discussed change disclosed on 29 October: a fresh round of employee share awards granted against a share base that has fallen by more than a third since the summer.
The question for shareholders is how much of the Capital returned through the tender offer and Buybacks could, in time, be reissued to staff and directors.
How the share count changed
After shareholders approved it on 7 July 2026, Redcentric (LSE:RCN) repurchased 56,250,000 shares through a tender offer, equal to roughly 35.1% of its then issued capital, following the sale of its data centre business. A subsequent buyback reduced the issued total to 103,071,740 shares. A new programme of up to £1.5m began on 29 October and is scheduled to run until 11 December. Shares held in treasury rose from 1,520,396 at the end of October to 1,788,285 after the 13 November purchase.
What was granted in October
The company (LSE:RCN) granted 2,629,502 Options under its 2016 long term incentive plan and 1,339,450 restricted share awards. The restricted awards replace cash bonuses accrued for the year to March 2026 and require recipients to stay for up to two years. Chief financial officer Tim Sykes received 890,322 LTIP options and chief executive Michelle Senecal de Fonseca received 462,428 restricted awards.
Most LTIP options vest only if absolute total Shareholder return beats the base price by at least 5% a year, with a quarter vesting at that level and full vesting at 10% a year. Mr Sykes' options use a 124 pence base price, matching earlier grants to the chief executive, while other staff use 114.65 pence. These bases are taken from the grant terms and are not current market prices.
The dilution arithmetic
After the grants, options were outstanding over 11,542,497 shares. The company said this was about 7.2% of the Issued Capital before the tender, but 11.2% of the current total. Because the tender removed shares while existing awards stayed unchanged, the remuneration committee decided to recalculate its dilution headroom on the reduced share count, so that the guideline sits where it was before the tender.
The new £1.5m programme, even if fully used, would retire only part of that overhang. As an illustration, 11.5 million shares compares with the 56.25 million retired through the tender, so outstanding awards equal roughly a fifth of the shares removed in July. Not every option will vest, since performance hurdles apply, but holders should treat buybacks and share awards together rather than separately.
Why it matters and the factors to watch
Management argues that stretching, share-based awards align staff with investors better than cash, and two non-executive directors bought shares in late October. Against that, the headroom adjustment means future grants can be sized against a smaller base, and institutional guidelines on dilution are applied by investors, not enforced by law. Trading also matters: the 27 October update guided to Revenue of about £63.7m for the six months to 30 September, down from £66.8m, with adjusted EBITDA flat at £9.1m and net Debt near £5.0m. If revenue keeps falling, TSR hurdles become harder to reach.
Dates to watch
Interim results are expected in the week commencing 7 December 2026, when the board anticipates resuming an interim dividend. The buyback is due to end on 11 December. The board has said it will keep shareholders informed on its dilution position. Investors will also look for the interim statement to update the share count, treasury holding and any further grants made since late October.
_11_17_2026_13_02_33_759778.jpg)





Please wait processing your request...